Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,841 companies covered, latest filing Oct 23.

  • $79.2M bought by 61 insiders at 47 companies
  • $239M sold by 49 insiders outside a trading plan
  • $2.5B sold by 203 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past week, each insider's filings added up.

  1. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    1,430,631 shares at $34.37 Oct 15–21, 5 filings +1.1% to stake 2 superinvestors bought in Q2
    $49.2M
  2. DOLEDole PLC
    Pale Fire Capital SE10% owner, +4 joint filers
    648,356 shares at $13.19 Oct 20–22 +6.7% to stake
    $8.6M
  3. APLDApplied Digital
    Jason Gechen ZhangPresident
    300,000 shares at $18.86 Oct 16 +12% to stake 5 superinvestors bought in Q2
    $5.7M
  4. RENTRent the Runway
    STORY3 Capital Partners, LLCDirector, +3 joint filers
    632,922 shares at $3.55 Oct 21 +15% to stake
    $2.2M
  5. RENTRent the Runway
    CHS US Investments LLC10% owner, +4 joint filers
    458,245 shares at $3.55 Oct 21 +2% to stake
    $1.6M
  6. FBKFB Financial
    Orrin H Ingram IIDirector
    29,081 shares at $52.88 Oct 20 +31% to stake
    $1.5M
  7. TENXTenax Therapeutics
    ADAR1 Capital Management, LLC10% owner, +1 joint filer
    922,849 shares at $1.59 Oct 19–21 +14% to stake
    $1.5M
  8. APLDApplied Digital
    Wes CumminsCEO
    55,803 shares at $18.04 Oct 16 +1% to stake 5 superinvestors bought in Q2
    $1M
  9. RAPPRapport Therapeutics
    Steven M PaulDirector
    35,714 shares at $27.28 Oct 22 +86% to stake
    $974K
  10. SNESSenesTech
    Glenbrook Capital Management10% owner
    1,087,679 shares at $0.7200 Oct 15–22, 2 filings
    $781K

Biggest sales

Past week, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    43,111 shares at $46,654.38 Oct 20 0.5% of stake Planned sale (10b5-1)
    $2B
  2. SNOWSnowflake
    Frank SlootmanDirector
    300,000 shares at $316.43 Oct 19 94% of stake Planned sale (10b5-1)
    $94.9M
  3. TALOTalos Energy
    Empresarial De Capitales S.a. De C.v. Control10% owner
    4,893,590 shares at $17.55 Oct 15–19, 2 filings 17% of stake
    $85.9M
  4. TRVTravelers
    Alan D SchnitzerCEO
    88,900 shares at $396.77 Oct 21 23% of stake
    $35.3M
  5. PATHUiPath
    Daniel DinesCEO
    2,500,000 shares at $13.23 Oct 15–16 7.9% of stake Planned sale (10b5-1)
    $33.1M
  6. UTHRUnited Therapeutics
    Martine A RothblattCEO
    47,500 shares at $555.06 Oct 16–22, 5 filings 13% of stake Planned sale (10b5-1)
    $26.4M
  7. MUMicron Technology
    Scott J DeboerPres. & Chief Tech & Prod Offr
    28,545 shares at $900.00 Oct 16 16% of stake Planned sale (10b5-1)
    $25.7M
  8. ALMRAlamar Biosciences
    Qiming Corporate GP VI, Ltd.10% owner, +6 joint filers
    733,811 shares at $28.64 Oct 15–22, 3 filings 29% of stake
    $21M
  9. SNOWSnowflake
    Benoit DagevilleDirector
    50,000 shares at $321.74 Oct 21 2.1% of stake Planned sale (10b5-1)
    $16.1M
  10. LINDLindblad Expeditions
    Sven-Olof LindbladDirector
    403,674 shares at $35.31 Oct 16–22, 2 filings 3.8% of stake Planned sale (10b5-1)
    $14.3M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 6 insiders, $1.7M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more

    Latest buy Oct 23 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Joel L. Frank Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

RLAY insider trades

Every open-market buy and sale in RLAY, one row per filing, newest first

RLAY page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Sanjiv Patel CEO
    RLAYRelay Therapeutics
    Planned sale
    $872K 48,199 shares at $18.10 9.3% of stake
    Traded Oct 7 Filed Oct 8
    ↗
  2. Thomas Catinazzo CFO
    RLAYRelay Therapeutics
    Planned sale
    $329K 17,717 shares at $18.59 14% of stake
    Traded Oct 6 Filed Oct 8
    ↗
  3. Donald A Bergstrom President, R&D
    RLAYRelay Therapeutics
    Planned sale
    $162K 8,530 shares at $18.97 2.1% of stake
    Traded Sep 8 Filed Sep 9
    ↗
  4. Thomas Catinazzo CFO
    RLAYRelay Therapeutics
    Planned sale
    $336K 17,717 shares at $18.94 13% of stake
    Traded Sep 8 Filed Sep 9
    ↗
  5. Sanjiv Patel CEO
    RLAYRelay Therapeutics
    Planned sale
    $913K 48,199 shares at $18.94 8.5% of stake
    Traded Sep 8 Filed Sep 9
    ↗
  6. SVF Pauling (Cayman) Ltd 10% owner, +2 joint filers
    RLAYRelay Therapeutics
    Sale
    $116M 6,000,000 shares at $19.40 22% of stake
    Traded Aug 25 Filed Aug 28
    ↗
  7. Peter Rahmer See remarks
    RLAYRelay Therapeutics
    Planned sale
    $90K 4,508 shares at $20.03 2% of stake
    Traded Aug 26 Filed Aug 28
    ↗
  8. Sanjiv Patel CEO
    RLAYRelay Therapeutics
    Planned sale
    $980K 48,199 shares at $20.33 7.8% of stake
    Traded Aug 17 Filed Aug 18
    ↗
  9. Thomas Catinazzo CFO
    RLAYRelay Therapeutics
    Planned sale
    $350K 17,717 shares at $19.74 11% of stake
    Traded Aug 14 Filed Aug 18
    ↗
  10. Donald A Bergstrom President, R&D
    RLAYRelay Therapeutics
    Planned sale
    $162K 8,660 shares at $18.71 2.1% of stake
    Traded Jul 6 Filed Jul 8
    ↗
  11. Sanjiv Patel CEO
    RLAYRelay Therapeutics
    Planned sale
    $944K 48,199 shares at $19.58 7.3% of stake
    Traded Jul 7 Filed Jul 8
    ↗
  12. Thomas Catinazzo CFO
    RLAYRelay Therapeutics
    Planned sale
    $331K 17,717 shares at $18.69 10% of stake
    Traded Jul 6 Filed Jul 8
    ↗
  13. Peter Rahmer See remarks
    RLAYRelay Therapeutics
    Planned sale
    $955K 50,000 shares at $19.09 18% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  14. Thomas Catinazzo CFO
    RLAYRelay Therapeutics
    Planned sale
    $3.2M 187,163 shares at $16.97 51% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  15. Donald A Bergstrom President, R&D
    RLAYRelay Therapeutics
    Planned sale
    $1.6M 93,456 shares at $16.94 18% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  16. Thomas Catinazzo CFO
    RLAYRelay Therapeutics
    Planned sale
    $228K 17,717 shares at $12.86 8.3% of stake
    Traded May 14 Filed May 14
    ↗
  17. Thomas Catinazzo CFO
    RLAYRelay Therapeutics
    Planned sale
    $257K 19,517 shares at $13.19 8.4% of stake
    Traded Apr 7–9 Filed Apr 9
    ↗
  18. Thomas Catinazzo CFO
    RLAYRelay Therapeutics
    Planned sale
    $178K 17,717 shares at $10.06 7.1% of stake
    Traded Mar 9 Filed Mar 11
    ↗
  19. Peter Rahmer See remarks
    RLAYRelay Therapeutics
    Sale
    $160K 21,394 shares at $7.50 6% of stake
    Traded Oct 29, 2025 Filed Oct 30, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,841 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.